Virtual Library
Start Your Search
R. Elias
Author of
-
+
P3.02c - Poster Session with Presenters Present (ID 472)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 12/07/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P3.02c-081 - Complete Blood Count Parameters as Predictive Factors in Patients with Advanced Non-Small Cell Lung Cancer Treated with Nivolumab (ID 6150)
14:30 - 14:30 | Author(s): R. Elias
- Abstract
Background:
Checkpoint inhibitors such as nivolumab (anti-PD1) represent a recent breakthrough in the management of patients with advanced non-small cell lung cancer (NSCLC) after disease progression following initial platinum-based therapy. Prospective identification of likely responders remains a challenge as PDL-1 testing, while helpful, is imperfect. Identifying additional indicators is warranted. Studies in melanoma patients demonstrated that analyzing some baseline clinical laboratory parameters had predictive value in the setting of immunotherapy (Weide et al Clin Can Res 2016, and Ferrucci et al BJC 2015). We attempted the same in our lung cancer population.
Methods:
We performed a retrospective analysis in a patient population with biopsy proven advanced NSCLC who received nivolumab. Patient charts were reviewed to obtain data on demographics, ECOG performance status, stage, number of previous therapies, and baseline complete blood count (CBC), from which the ratio of absolute neutrophil count (ANC) to absolute lymphocyte count (ALC) was calculated. Imaging data for response assessment were available. Univariate analysis was performed to study the association between clinical and demographic parameters and progression-free survival (PFS) using SAS software.
Results:
In our cohort of 114 patients treated during 2015-2016, the median follow-up was 5.4 months (range 0-15.8), median age was 67 years (range 40-91), and median number of prior therapies was 2. There were 52% males, 60% Caucasians, 32% Hispanics, 8% African Americans, and 75% had ECOG performance status of 0-1. Our univariate analysis showed the following: Figure 1
Conclusion:
Our data indicates that low baseline ANC/ALC (<5), female gender, and ECOG 0-1 are independent factors associated with significantly favorable PFS in patients with advanced NSCLC treated with nivolumab. A more detailed analysis of a larger cohort, including data on mutational burden, will be presented.
